Corticotropin-releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional-arousal circuit during expectation of abdominal pain

Journal of Neuroscience

Volumn 31, Issue 35, 2011, Pages 12491-12500

  Hubbard, Catherine S ^a   Labus, Jennifer S ^a   Bueller, Joshua ^a   Stains, Jean ^a   Suyenobu, Brandall ^a   Dukes, George E ^c   Kelleher, Dennis L ^c   Tillisch, Kirsten ^a   Naliboff, Bruce D ^a,b   Mayer, Emeran A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; EMICERFONT; PLACEBO;

ABDOMINAL PAIN; ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ANXIETY; AROUSAL; ARTICLE; BOLD SIGNAL; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MECHANISM; EMOTION; EXPECTATION; FEAR; FEMALE; FUNCTIONAL ANATOMY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULA; IRRITABLE COLON; LOCUS CERULEUS; NERVE CELL NETWORK; NEUROANATOMY; PAIN THRESHOLD; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STATE TRAIT ANXIETY; STRESS;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; BRAIN MAPPING; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEURAL PATHWAYS; OXYGEN; PAIN MEASUREMENT; PAIN THRESHOLD; PYRAZOLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 80052374213     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1860-11.2011     Document Type: Article

References (69)

1. Aguilera G, Millan MA, Hauger RL, Catt KJ (1987) Corticotropin-releasing factor receptors: distribution and regulation in brain, pituitary, and peripheral tissues. Ann NY Acad Sci 512:48-66.
2. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12.
3. Aston-Jones G, Cohen JD (2005) An integrative theory of locus coeruleusnorepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci 28:403-450.
4. Bale TL, Vale WW (2004) CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:525-557.
5. Bangasser DA, Curtis A, Reyes BAS, Bethea TT, Parastatidis I, Ischiropoulos H, Van Bockstaele EJ, Valentino RJ (2010a) Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol Psychiatry 15:877, 896-904.
6. Bangasser D, Zhang X, Valentino R (2010b) Sex differences in locus coeruleus dendritic morphology. Soc Neurosci Abstr 36:190.21.
7. Berman SM, Naliboff BD, Suyenobu B, Labus JS, Stains J, Ohning G, Kilpatrick L, Bueller JA, Ruby K, Jarcho J, Mayer EA (2008) Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome. J Neurosci 28:349-359.
8. Blankstein U, Chen J, Diamant NE, Davis KD (2010) Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 138:1783-1789.
9. Buxton RB (2002) Introduction to functional magnetic resonance imaging. Cambridge, UK: Cambridge UP.
10. Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, Mayer M, Vuong T, Hirano M, Naliboff BD, Ameen VZ, Mayer EA (2009) Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 21:149-159.
11. Chen Y, Brunson KL, Müller MB, Cariaga W, Baram TZ (2000) Immunocytochemical distribution of corticotropin-releasing hormone receptor type-1 (CRF1)-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the c-terminus. J Comp Neurol 420:305-323.
12. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27:417-425.
13. Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23:71-77.
14. Di Fabio R, St-Denis Y, Sabbatini FM, Andreotti D, Arban R, Bernasconi G, Braggio S, Blaney FE, Capelli AM, Castiglioni E, Di Modugno E, Donati D, Fazzolari E, Ratti E, Feriani A, Contini S, Gentile G, Ghirlanda D, Provera S, Marchioro C, et al. (2008) Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists. J Med Chem 51:7370-7379.
15. 1) receptor antagonist (RA) GW876008 in irritable bowel syndrome (IBS) patients (Pts). Neurogastroenterol Motil 21:84.
16. Dunn AJ, Berridge CW (1990) Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 15:71-100.
17. Elsenbruch S, Rosenberger C, Bingel U, Forsting M, Schedlowski M, Gizewski ER (2010a) Patients with irritable bowel syndrome have altered emotional modulation of neural responses to visceral stimuli. Gastroenterology 139:1310-1319.
18. Elsenbruch S, Rosenberger C, Enck P, Forsting M, Schedlowski M, Gizewski ER (2010b) Affective disturbances modulate the neural processing of visceral pain stimuli in irritable bowel syndrome: an fMRI study. Gut 59:489-495.
19. Fukudo S (2007) Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol 42:48-51.
20. Fukudo S, Nomura T, Hongo M (1998) Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 42:845-849.
21. Gracely RH, McGrath F, Dubner R (1978) Ratio scales of sensory and affective verbal pain descriptors. Pain 5:5-18.
22. Holroyd KA, Labus JS, Carlson B (2009) Moderation and mediation in the psychological and drug treatment of chronic tension-type headache: the role of disorder severity and psychiatric comorbidity. Pain 143:213-222.
23. Joreskog KG (1971) Simultaneous factor analysis in several populations. Psychometrika 36:409-426.
24. Jutkiewicz EM, Wood SK, Houshyar H, Hsin LW, Rice KC, Woods JH (2005) The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology 180:215-223.
25. Keren NI, Lozar CT, Harris KC, Morgan PS, Eckert MA (2009) In vivo mapping of the human locus coeruleus. Neuroimage 47:1261-1267.
26. Kosoyan HP, Grigoriadis DE, Taché Y (2005) The CRF1 receptor antagonist, NBI-35965, abolished the activation of locus coeruleus neurons induced by colorectal distension and intracisternal CRF in rats. Brain Res 1056:85-96.
27. Kumari V, Das M, Taylor PJ, Barkataki I, Andrew C, Sumich A, Williams SC, Ffytche DH (2009) Neural and behavioural responses to threat in men with a history of serious violence and schizophrenia or antisocial personality disorder. Schizophr Res 110:47-58.
28. Künzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37:525-533.
29. Labus JS, Naliboff BN, Fallon J, Berman SM, Suyenobu B, Bueller JA, Mandelkern M, Mayer EA (2008) Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 41:1032-1043.
30. Lembo T, Plourde V, Shui Z, Fullerton S, Mertz H, Tache Y, Sytnik B, Munakata J, Mayer E (1996) Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol Motil 8:9-18.
31. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480-1491.
32. Martinez V, Taché Y (2006) CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 12:4071-4088.
33. Mayer EA (2000) The neurobiology of stress and gastrointestinal disease. Gut 47:861-869.
34. McIntosh AR, Gonzalez-Lima F (1994) Structural equation modeling and its application to network analysis in functional brain imaging. Hum Brain Mapping 2:2-22.
35. Millan MA, Jacobowitz DM, Hauger RL, Catt KJ, Aguilera G (1986) Distribution of corticotropin-releasing factor receptors in primate brain. Proc Natl Acad Sci U S A 83:1921-1925.
36. 1 receptor antagonist, NBI 35965, blunts stressinduced visceral hyperalgesia and colonic motor function in rats. Brain Res 985:32-42.
37. Naliboff BD, Waters AM, Labus JS, Kilpatrick L, Craske MG, Chang L, Negoro H, Ibrahimovic H, Mayer EA, Ornitz E (2008) Increased acoustic startle responses in IBS patients during abdominal and nonabdominal threat. Psychosom Med 70:920-927.
38. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR (2005) 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 8:828-834.
39. Phelps EA, O'Connor KJ, Gatenby JC, Gore JC, Grillon C, Davis M (2001) Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci 4:437-441.
40. Radulovic J, Sydow S, Spiess J (1998) Characterization of native corticotropinreleasing factor receptor type 1 (CRFR1) in the rat and mouse central nervous system. J Neurosci Res 54:507-521.
41. Rapps N, van Oudenhove L, Enck P, Aziz Q (2008) Brain imaging of visceral functions in healthy volunteers and IBS patients. J Psychosom Res 64:599-604.
42. Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y, Shoji T, Karahashi K, Hongo M, Fukudo S (2004) Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53:958-964.
43. Sánchez MM, Young LJ, Plotsky PM, Insel TR (1999) Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408:365-377.
44. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA (1999) Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 94:2929-2935.
45. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD 3rd, Winston EN, Chen YL, Heym J (1996) CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93:10477-10482.
46. Schweinhardt P, Kuchinad A, Pukall CF, Bushnell MC (2008) Increased gray matter density in young women with chronic vulvar pain. Pain 140:411-419.
47. Seminowicz DA, Labus JS, Bueller JA, Tillisch K, Naliboff BD, Bushnell C, Mayer EA (2010) Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 139:48-57. e2.
48. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33.
49. Simpson JR Jr, Drevets WC, Snyder AZ, Gusnard DA, Raichle ME (2001) Emotion-induced changes in human medial prefrontal cortex. II. During anticipatory anxiety. Proc Natl Acad Sci U S A 98:688-693.
50. Smith MA, Davidson J, Ritchie JC, Kudler H, Lipper S, Chappell P, Nemeroff CB (1989) The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry 26:349-355.
51. Spielberger CD (1983) Manual for the State-Trait Anxiety Inventory (STAI). Palo Alto, CA: Consulting Psychologists Press.
52. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P (2007) Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56:1770-1798.
53. Stein JL, Wiedholz LM, Bassett DS, Weinberger DR, Zink CF, Mattay VS, Meyer-Lindenberg A (2007) A validated network of effective amygdala connectivity. Neuroimage 36:736-745.
54. Straube T, Schmidt S, Weiss T, Mentzel HJ, Miltner WH (2009) Dynamic activation of the anterior cingulate cortex during anticipatory anxiety. Neuroimage 44:975-981.
55. Sweetser S, Camilleri M, Linker Nord SJ, Burton DD, Castenada L, Croop R, Tong G, Dockens R, Zinsmeister AR (2009) Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol 296:G1299-G1306.
56. Taché Y, Kiank C, Stengel A (2009) A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep 11:270-277.
57. 2 receptors in fear and anxiety. Neurosci Biobehav Rev 25:627-636.
58. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA, Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE (2000) C. Functional bowel disorders and D. Functional abdominal pain. In: Rome II: the functional gastrointestinal disorders diagnosis, pathophysiology and treatment: a multinational consensus (Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, eds), pp 351-432. McLean, VA: Degnon Associates.
59. Thoua NM, Hobson AR, Dukes GE, Kelleher D, Hicks K, Boardley R, Raeburn A, Emmanuel A (2009) The selective CRF-1 receptor antagonist GW876008 attenuates stress induced rectal hypersensitivity in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil [Suppl] 21:85.
60. Trimble N, Johnson AC, Foster A, Greenwood-van Meerveld B (2007) Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol Motil 19:754-760.
61. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213:1394-1397.
62. Valentino RJ, Foote SL (1987) Corticotropin-releasing factor disrupts sensory responses of brain noradrenergic neurons. Neuroendocrinology 45:28-36.
63. Valentino RJ, Foote SL (1988) Corticotropin-releasing hormone increases tonic but not sensory-evoked activity of noradrenergic locus coeruleus neurons in unanesthetized rats. J Neurosci 8:1016-1025.
64. Valentino RJ, Foote SL, Aston-Jones G (1983) Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res 270:363-367.
65. Valentino RJ, Miselis RR, Pavcovich LA (1999) Pontine regulation of pelvic viscera: Pharmacological target for pelvic visceral dysfunction. Trends Pharmacol Sci 20:253-260.
66. Van Bockstaele EJ, Reyes BA, Valentino RJ (2010) The locus coeruleus: a key nucleus where stress and opioids intersect to mediate vulnerability to opiate abuse. Brain Res 1314:162-174.
67. Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063-1070.
68. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361-370.
69. Zorrilla EP, Koob GF (2010) Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15:371-383.